Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Not Confirmed
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Not Confirmed
Not Confirmed
18-21 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
STLE Annual MeetingSTLE Annual Meeting
Industry Trade Show
Not Confirmed
18-22 May, 2025
American Thoracic Soci...American Thoracic Society
Industry Trade Show
Not Confirmed
18-21 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions
13 Sep 2021
// ENDPTS
https://endpts.com/serial-entrepreneur-gary-glick-sells-another-one-of-his-startups-for-290m-this-time-to-an-unlikely-buyer/
02 Dec 2019
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ifm-therapeutics-announces-55-5-million-financing-to-launch-and-fund-new-subsidiaries-and-appointment-of-dr-h-martin-seidel-as-chief-executive-officer-300967030.html
02 Dec 2019
// A. A Idrus FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/ifm-gets-new-ceo-bags-another-55m-to-launch-incubator-new-subsidiaries
02 Dec 2019
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/ifm-therapeutics-announces-55-5-million-financing-to-launch-and-fund-new-subsidiaries-and-appointment-of-dr-h-martin-seidel-as-chief-executive-officer-300967030.html
21 Nov 2019
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-research-demonstrates-second-direct-link-between-inflammasome-activation-and-alzheimers-disease-300962374.html
06 Sep 2019
// Amirah.A. Drus FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/novartis-bankrolls-ifm-due-s-cgas-sting-pipeline-840m-buyout-option
Details:
Novartis’ acquisition of IFM Due provides full rights to its STING antagonist portfolio, targeting inflammation-driven diseases marked by excessive interferon and pro-inflammatory cytokine signaling.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $835.0 million Upfront Cash: $90.0 million
Deal Type: Acquisition March 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $835.0 million
Deal Type : Acquisition
Novartis Acquires IFM for STING Antagonist Program Development
Details : Novartis’ acquisition of IFM Due provides full rights to its STING antagonist portfolio, targeting inflammation-driven diseases marked by excessive interferon and pro-inflammatory cytokine signaling.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $90.0 million
March 13, 2024
ABOUT THIS PAGE